Abstract 471TiP
Background
Neurokinin-1 (NK-1) receptor antagonists will prevent CINV effectively but are not affordable for patients of low socioeconomic status and there is still an unmet need for the prevention of CINV in the low socio-economic setting. Recent studies show olanzapine which blocks multiple neurotransmitters in the brain is also effective in preventing CINV and pregabalin which inhibits the release of neurotransmitters is effective in preventing postoperative nausea and vomiting. A mechanistic synergism is expected between the olanzapine and pregabalin combination. Therefore, this trial was designed to evaluate the add-on combination of olanzapine and pregabalin in the management of CINV.
Trial design
This trial is a group sequential response adaptive randomized double-blinded clinical trial. The O'Brien-Fleming boundaries were defined for efficacy and futility. The total sample size to achieve the primary objective of the difference in the proportion of patients with “overall no nausea” was calculated to be 84, with an allocation ratio of 1:1. Depending on the results of each interim analysis, the allocation ratio will be changed, and more patients will be allocated to the well-performing arm. In our study, we enrolled cancer patients belonging to low socio-economic status who planned to receive highly emetogenic cancer chemotherapeutic agents and the standard of care antiemetic premedication (ondansetron 8mg and dexamethasone 8mg). Patients received either olanzapine 5 mg plus pregabalin 75 mg orally or a matching placebo daily on day 1 through day 5 in addition to their standard antiemetic premeditations. In stage one of the trial, 30 patients were equally randomized into two groups and the interim analysis showed the experimental group performed better in terms of “overall no nausea” (40% vs. 6.6 % p value-0.042). However, it didn't breach the boundary (0.0035) fixed by the O'Brien and Fleming approach. So, the trial is being continued to the second stage. As the Z (1.73) value was between 1.5-2, the allocation ratio has been changed to 2:1 for the next stage of the trial as per the protocol.
Clinical trial identification
CTRI/2021/08/035451.
Legal entity responsible for the study
The authors.
Funding
Indian Council of Medical Research (ICMR), India.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
26P - Subcutaneous trastuzumab versus intravenous trastuzumab for treatment of patients with HER2-positive breast cancer: A time, motion and cost-benefit assessment in a day care oncology unit in China
Presenter: Bei Sun
Session: Poster Display
Resources:
Abstract
27P - The biological characteristics of HER2-low in TNBC using mRNA profiling and molecular subtypes
Presenter: Asako Tsuruga
Session: Poster Display
Resources:
Abstract
28P - One-week ultra-hypofractionated partial breast RT in early breast cancer: 3DCRT vs IMRT
Presenter: Nurilla Zaynutdinov
Session: Poster Display
Resources:
Abstract
30P - Stereotactic body radiotherapy using cyberknife versus interstitial brachytherapy in accelerated partial breast irradiation on left-sided breast: A comparison of preliminary clinical result and dosimetric characteristics
Presenter: Ting-Na Wei
Session: Poster Display
Resources:
Abstract
31P - Prognostic implication of breast edema on preoperative breast MRI in breast cancer
Presenter: Ki-tae Hwang
Session: Poster Display
Resources:
Abstract
32P - Efficacy of olanzapine in the prophylaxis of delayed chemotherapy-induced nausea and vomiting in breast cancer patients receiving dose-dense AC with a steroid-sparing regimen: A single-center pilot study
Presenter: Manami Tada
Session: Poster Display
Resources:
Abstract
34P - Social support as the mediator of the association between unmet needs and happiness among women with early breast cancer
Presenter: Nithiya Sinarajoo
Session: Poster Display
Resources:
Abstract
35P - Prospective study assessing the efficacy and safety of a scalp cooling device for the prevention of alopecia in breast cancer patients undergoing (neo)adjuvant chemotherapy
Presenter: Winnie Yeo
Session: Poster Display
Resources:
Abstract
37P - To excise or not to excise: Preventive management of early breast cancer in atypical ductal hyperplasia patients
Presenter: Clarisse Hing
Session: Poster Display
Resources:
Abstract
38P - Exploring prognostic factors in patients achieving PCR after neoadjuvant therapy for triple-negative breast cancer: A retrospective study based on SEER data
Presenter: Lv Wenjie
Session: Poster Display
Resources:
Abstract